JPS4935635B1
(fr)
|
1970-12-28 |
1974-09-25 |
|
|
CH563405A5
(fr)
|
1971-09-10 |
1975-06-30 |
Duschinsky Robert Dr Schweiz I |
|
DE2226295A1
(de)
|
1972-05-30 |
1973-12-20 |
Henning Berlin Gmbh |
Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
|
DE2342479A1
(de)
|
1973-08-23 |
1975-03-13 |
Merck Patent Gmbh |
Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
|
GB2001976B
(en)
|
1977-08-03 |
1982-03-10 |
Yamasa Shoyu Kk |
S-adenosyl-l-methionine compositions and production thereof
|
US4849311A
(en)
|
1986-09-24 |
1989-07-18 |
Toa Nenryo Kogyo Kabushiki Kaisha |
Immobilized electrolyte membrane
|
US4968697A
(en)
|
1987-02-04 |
1990-11-06 |
Ciba-Geigy Corporation |
2-substituted adenosine 5'-carboxamides as antihypertensive agents
|
US5219840A
(en)
|
1987-04-06 |
1993-06-15 |
Sandoz Ltd. |
Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
|
US5221763A
(en)
*
|
1987-04-30 |
1993-06-22 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
US5591887A
(en)
*
|
1987-04-30 |
1997-01-07 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
ATE101342T1
(de)
|
1988-09-06 |
1994-02-15 |
Kabi Pharmacia Ab |
Prostaglandinderivate zur behandlung des gruenen stars oder einer okularen hypertension.
|
US6187813B1
(en)
|
1990-04-10 |
2001-02-13 |
Pharmacia & Upjohn Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5296504A
(en)
|
1988-09-06 |
1994-03-22 |
Kabi Pharmacia |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5140015A
(en)
|
1990-02-20 |
1992-08-18 |
Whitby Research, Inc. |
2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
|
US5280015A
(en)
|
1990-09-05 |
1994-01-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
|
JP3020580B2
(ja)
|
1990-09-28 |
2000-03-15 |
株式会社日立製作所 |
マイクロ波プラズマ処理装置
|
US5206222A
(en)
|
1991-05-22 |
1993-04-27 |
Vanderbilt University |
Methods for the reduction of myocardial reperfusion injury
|
HU212570B
(en)
*
|
1991-06-24 |
1996-08-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
|
US5407793A
(en)
|
1991-10-18 |
1995-04-18 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
An aqueous heart preservation and cardioplegia solution
|
US5278150A
(en)
|
1992-04-24 |
1994-01-11 |
Whitby Research, Inc. |
2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
|
DK62692D0
(fr)
|
1992-05-14 |
1992-05-14 |
Novo Nordisk As |
|
WO1994002497A1
(fr)
|
1992-07-15 |
1994-02-03 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Derives sulfo d'adenosine
|
US5972991A
(en)
*
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5338430A
(en)
|
1992-12-23 |
1994-08-16 |
Minnesota Mining And Manufacturing Company |
Nanostructured electrode membranes
|
US5443836A
(en)
|
1993-03-15 |
1995-08-22 |
Gensia, Inc. |
Methods for protecting tissues and organs from ischemic damage
|
DE69428536T2
(de)
|
1993-07-13 |
2002-06-06 |
Nasa |
A3 -adenosin -rezeptor agonisten
|
US5589467A
(en)
|
1993-09-17 |
1996-12-31 |
Novo Nordisk A/S |
2,5',N6-trisubstituted adenosine derivatives
|
WO1995011681A1
(fr)
|
1993-10-29 |
1995-05-04 |
Merck & Co., Inc. |
Antagonistes du recepteur de l'adenosine humaine
|
US5620676A
(en)
|
1994-03-08 |
1997-04-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biologically active ATP analogs
|
EP0704215A3
(fr)
|
1994-06-02 |
1998-04-01 |
Takeda Chemical Industries, Ltd. |
Inhibiteur de l'aumentation de la perméabilité vasculaire
|
GB9414193D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
US5801159A
(en)
|
1996-02-23 |
1998-09-01 |
Galileo Laboratories, Inc. |
Method and composition for inhibiting cellular irreversible changes due to stress
|
CN1164122A
(zh)
|
1996-03-01 |
1997-11-05 |
株式会社日立制作所 |
等离子处理机及其处理方法
|
AU2022497A
(en)
|
1996-03-13 |
1997-10-01 |
Novo Nordisk A/S |
A method of treating disorders related to cytokines in mammals
|
WO1997033879A1
(fr)
|
1996-03-15 |
1997-09-18 |
Merck & Co., Inc. |
Composes et methodes d'inhibition selective de l'activation du recepteur a3 de l'adenosine chez l'homme
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
US6211165B1
(en)
|
1997-05-09 |
2001-04-03 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
|
JP2001519386A
(ja)
|
1997-10-15 |
2001-10-23 |
トーマス・ジェファーソン・ユニバーシティ |
哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
|
WO1999020284A1
(fr)
|
1997-10-23 |
1999-04-29 |
Trustees Of The University Of Pennsylvania |
Procedes utiles pour reduire des lesions ischemiques du coeur par l'administration sequentielle d'agents de lipide a monophosphoryle et de recepteurs d'adenosine
|
GB9723566D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
GB9723590D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
FR2775901B1
(fr)
|
1998-03-13 |
2000-07-21 |
Logeais Labor Jacques |
Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
|
GB9813535D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
ATE290910T1
(de)
|
1998-07-16 |
2005-04-15 |
Univ Pennsylvania |
Verwendung von a3-adenosine antagonisten zur herstellung eines arzneimittels zur senkung des augeninnendrucks
|
DE69932173T2
(de)
|
1998-10-16 |
2007-06-06 |
Pfizer Inc. |
Adeninderivate
|
IL127947A0
(en)
|
1999-01-07 |
1999-11-30 |
Can Fite Technologies Ltd |
Pharmaceutical use of adenosine agonists
|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
US6214807B1
(en)
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
IL147194A0
(en)
|
1999-06-22 |
2002-08-14 |
Cv Therapeutics Inc |
Thiophene a2a receptor agonists
|
US6180615B1
(en)
|
1999-06-22 |
2001-01-30 |
Cv Therapeutics, Inc. |
Propargyl phenyl ether A2A receptor agonists
|
IL133680A0
(en)
|
1999-09-10 |
2001-04-30 |
Can Fite Technologies Ltd |
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
US6368573B1
(en)
|
1999-11-15 |
2002-04-09 |
King Pharmaceuticals Research And Development, Inc. |
Diagnostic uses of 2-substituted adenosine carboxamides
|
US6258793B1
(en)
|
1999-12-03 |
2001-07-10 |
Cv Therapeutics, Inc. |
N6 heterocyclic 5′ modified adenosine derivatives
|
GB9930071D0
(en)
|
1999-12-20 |
2000-02-09 |
Glaxo Group Ltd |
Medicaments
|
GB0003960D0
(en)
|
2000-02-18 |
2000-04-12 |
Pfizer Ltd |
Purine derivatives
|
US20010051612A1
(en)
|
2000-02-23 |
2001-12-13 |
Gloria Cristalli |
2-Thioether A2A receptor agonists
|
US20030010454A1
(en)
|
2000-03-27 |
2003-01-16 |
Bailey Andrew D. |
Method and apparatus for varying a magnetic field to control a volume of a plasma
|
US6534651B2
(en)
|
2000-04-06 |
2003-03-18 |
Inotek Pharmaceuticals Corp. |
7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
CA2417489A1
(fr)
|
2000-07-28 |
2002-02-07 |
Maria A. Peral |
Methode de reduction de la pression intraoculaire avec des derives d'indole
|
ATE292973T1
(de)
|
2001-01-16 |
2005-04-15 |
Can Fite Biopharma Ltd |
Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
|
GB2372742A
(en)
|
2001-03-03 |
2002-09-04 |
Univ Leiden |
C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
|
EP1241176A1
(fr)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Dérivés de purine pour le traitement de l'ischémie
|
US20040204481A1
(en)
|
2001-04-12 |
2004-10-14 |
Pnina Fishman |
Activation of natural killer cells by adenosine A3 receptor agonists
|
US20030013675A1
(en)
|
2001-05-25 |
2003-01-16 |
Boehringer Ingelheim Pharma Kg |
Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
|
US7713946B2
(en)
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
EP1423175B1
(fr)
|
2001-08-08 |
2013-10-02 |
Brown University Research Foundation |
Procedes de micronisation de medicaments hydrophobes
|
SG176313A1
(en)
|
2001-10-01 |
2011-12-29 |
Univ Virginia Patent Found |
2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
|
JP2005530736A
(ja)
|
2002-04-18 |
2005-10-13 |
シーブイ・セラピューティクス・インコーポレイテッド |
ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にa1アデノシンアゴニストを投与することを含む不整脈の処置方法
|
KR20040104566A
(ko)
|
2002-04-30 |
2004-12-10 |
알콘, 인코퍼레이티드 |
안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ctgf)의활성 및/또는 발현 조절, 저해, 또는 변조제
|
GB0216416D0
(en)
|
2002-07-15 |
2002-08-21 |
Novartis Ag |
Organic compounds
|
GB2436255B
(en)
|
2002-12-23 |
2007-11-28 |
Global Cardiac Solutions Pty L |
Organ preconditioning, arrest, protection, preservation and recovery
|
CA2551169A1
(fr)
|
2002-12-23 |
2004-07-08 |
Global Cardiac Solutions Pty Ltd |
Preconditionnement, retention, protection, conservation et recuperation d'organes
|
US8008338B2
(en)
|
2003-06-03 |
2011-08-30 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
WO2005070006A2
(fr)
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Composes nitroses et/ou nitrosyles, compositions et procede pour les utiliser
|
CN101010085B
(zh)
|
2004-05-26 |
2012-12-26 |
伊诺泰克制药公司 |
嘌呤衍生物作为腺苷a1受体激动剂及其用法
|
EP2221307A1
(fr)
|
2004-05-26 |
2010-08-25 |
Inotek Pharmaceuticals Corporation |
Derivés de purines agonistes du récepteur adénosine A1 et leur utilisation
|
CA2573682A1
(fr)
|
2004-07-12 |
2006-02-16 |
Cv Therapeutics, Inc. |
Procede pour la preparation d'agonistes du recepteur a1 de l'adenosine
|
DE502005008880D1
(de)
*
|
2004-10-18 |
2010-03-04 |
Polymun Scient Immunbio Forsch |
Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
|
WO2007002139A2
(fr)
|
2005-06-22 |
2007-01-04 |
The Trustees Of The University Of Pennsylvania |
Neuroprotection de cellules ganglionnaires de la retine
|
CN101321460A
(zh)
*
|
2005-11-30 |
2008-12-10 |
伊诺泰克制药公司 |
嘌呤衍生物及其用法
|
US7964191B2
(en)
|
2006-02-02 |
2011-06-21 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
US20070238694A1
(en)
|
2006-03-23 |
2007-10-11 |
Inotek Pharmaceuticals Corporation |
Purine compounds and methods of use thereof
|
US8163737B2
(en)
|
2006-06-13 |
2012-04-24 |
Vertex Pharmaceuticals Incorporated |
CGRP receptor antagonists
|
AR062046A1
(es)
|
2006-07-25 |
2008-08-10 |
Osmotica Pharmaceutical Argentina S A |
Soluciones oftalmicas
|
MX2009003750A
(es)
|
2006-10-06 |
2009-06-18 |
Univ Pennsylvania |
Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
|
KR101472602B1
(ko)
|
2006-11-10 |
2014-12-15 |
바스프 에스이 |
피프로닐의 결정질 변형물
|
AU2007327990A1
(en)
|
2006-12-05 |
2008-06-12 |
The Royal Institution For The Advancement Of Learning/ Mcgill University |
Methods of use of TRK receptor modulators
|
JP2008266143A
(ja)
|
2007-04-16 |
2008-11-06 |
Santen Pharmaceut Co Ltd |
アデノシン誘導体を有効成分として含有する緑内障治療剤
|
AU2008311251B9
(en)
|
2007-10-11 |
2014-04-17 |
Biogen Ma Inc. |
Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and TrkB agonists
|
WO2009076580A2
(fr)
|
2007-12-12 |
2009-06-18 |
Thomas Jefferson University |
Compositions et procédés pour le traitement et la prévention de maladies cardiovasculaires
|
JP2011511802A
(ja)
|
2008-02-07 |
2011-04-14 |
ギリアード・パロ・アルト・インコーポレイテッド |
Abca−1を上昇させる化合物およびかかる化合物の使用方法
|
CA2742871C
(fr)
|
2008-11-13 |
2018-10-23 |
Herb Lin |
Procedes et compositions pour la regulation de l'homeostasie du fer par modulation de la proteine bmp-6
|
CA2762064A1
(fr)
*
|
2009-05-01 |
2010-11-04 |
Inotek Pharmaceuticals Corporation |
Procede de reduction de la pression intraoculaire chez les humains
|
CA2774704A1
(fr)
|
2009-10-26 |
2011-05-05 |
Inotek Pharmaceuticals Corporation |
Preparation ophtalmique et son procede de fabrication
|
WO2011077435A1
(fr)
|
2009-12-22 |
2011-06-30 |
Bar-Ilan University |
Compositions et procédés pour la réduction de la pression intraoculaire
|
SG182285A1
(en)
|
2010-01-11 |
2012-08-30 |
Inotek Pharmaceuticals Corp |
Combination, kit and method of reducing intraocular pressure
|
US20110217262A1
(en)
|
2010-03-05 |
2011-09-08 |
Kornfield Julia A |
Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
|
WO2011116292A1
(fr)
*
|
2010-03-19 |
2011-09-22 |
Inotek Pharmaceuticals Corporation |
Compositions combinées d'agonistes d'adénosine a1 et de récepteurs adrénergiques bêta-bloquants non sélectifs pour abaisser la pression intraoculaire
|
ES2613254T3
(es)
|
2010-03-19 |
2017-05-23 |
Inotek Pharmaceuticals Corporation |
Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular
|
AU2011230580A1
(en)
*
|
2010-03-26 |
2012-10-11 |
Inotek Pharmaceuticals Corporation |
Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
|
EP2552932A4
(fr)
|
2010-03-26 |
2013-08-21 |
Inotek Pharmaceuticals Corp |
Composés d'adénosine et leur utilisation
|